Select a Region North America

Can the Thriving Pharmaceutical Industry in India Be a Major Opportunity for Japanese Pharma Companies Looking to Grow Rapidly?

Register for the Webinar: Can the thriving pharmaceutical industry in India be a major opportunity for Japanese pharma companies looking to grow rapidly?

With India experiencing transformational growth and reduced regulatory and administrative hurdles, life sciences companies worldwide are increasingly considering India a key market for clinical and commercial opportunities. With Advancements in the development and manufacturing biopharmaceuticals and biosimilars, investments in digital transformation and enhanced technology applications in the Supply Chain, India is emerging as a Global Pharma and Lifesciences Innovation Hub.

To hear more from our experts about how India can contribute to your life sciences company’s growth, join the webinar on July 3, 2024, at 12 PM Japan Time:

  • What are the growth drivers for India’s pharma and medical device industry
  • Understand the changes in regulatory and administrative hurdles and attitudes
  • Discuss how the industry is responding and what are the different scenarios that are likely to emerge
  • Advice on how new entrants should think about their business models and key success factors.

Date and Time: Wednesday, July 3, 2024, 12:00 PM – 1:00 PM (JST)

Format: Webinar (Zoom) presentations will be in English with simultaneous interpretation into Japanese.

Presenters

  • Monica Gangwani
    Executive Director, EVERSANA APAC,
    India
    Monica is Executive Director India, Advisory Services and brings almost thirty years of life sciences experience spanning sales, brand management and strategic market research. Monica began her career in sales and after 8 years in sales and brand management across leading companies like Wockhardt and Parke Davis (now Pfizer), she joined Nielsen to lead the healthcare practice for India. She then moved to Ipsos to set-up and establish the Healthcare Division of the Company, that she successfully led for twenty years. She has assisted many MNCs in understanding the India market landscape across therapy areas at the pre-launch stages including price testing, opportunity assessment and has also led engagements to assess the effectiveness of the launches.
  • Kushesh Gupta
    Senior Principal, EVERSANA, Japan
    Kushesh is a Senior Principal at EVERASANA. He brings ~12 years of experience in health care and life sciences, with more than 9 years of strategy consulting experience. During this time, Kushesh has worked with organizations like IQVIA, Alkem and DRG (Clarivate). Kushesh has worked with the entire spectrum of life sciences stakeholders in India including pharma (local and MNCs), biotech, MedTech, digital health, PE/VC (domestic and international) and policy makers (Planning commission, FICCI, OPPI, IDMA etc.). Kushesh is a medical doctor MBBS (MD equivalent) and has practiced for ~3 years as a doctor. Further, he earned his MBA from Indian Institute of Management (IIM), Ahmedabad.


Contact Information:
Yasuyo Tanaka, [email protected]

~~~~

国内ヘルスケア企業の皆様へ 弊社ウェビナーのお知らせ

 

インドのライフサイエンス市場は、急成長を目指す国内ライフサイエンス企業にとって大きなチャンスとなるとお考えでしょうか?

 

インドの過去の成長及び昨今実施された規制緩和や行政のハードルが下がったことで、世界のライフサイエンス企業はインドライフサイエンス市場を、臨床・ビジネスの観点から重要な市場と考えるようになってきています。特に、バイオ医薬品やバイオシミラーの開発・製造、デジタルトランスフォーメーションへの投資、サプライチェーンにおける技術応用の強化により、インドはグローバルライフサイエンス・イノベーションのハブとして注目を集めています。

 

本ウェビナーでは、以下について弊社専門家が詳しく解説します:

 

  • インドの製薬・医療機器産業の成長ドライバー
  • 規制・行政上のハードルや姿勢の変化
  • 業界の対応と考えられるシナリオ
  • 新規参入企業がビジネスモデルや主要成功要因について考慮すべき点

 

日時:2024年7月3日午後12時(日本時間)

言語:英語(日本語通訳付き)

 

皆様のご参加を心よりお待ちしております。